Healthcare / Diagnostics & ResearchParis
$0.19
-0.00 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.5M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$59M
P/E
19.4x
↓EV/EBITDA
19.2x
↑ROE
5.0%
↑Gross Margin
47.8%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+34.0%
FCF CAGR
—
FCF margin
1.0%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.3M · net income $1.4M · FCF $166000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.3M | $17.3M | $13.7M | $14.4M | $7.2M |
| Net Income | $1.4M | $1.4M | $902000.00 | $-5.3M | $-4.5M |
| EBITDA | $3.9M | $3.9M | $5.8M | $-2.2M | $-2.8M |
| EPS | 0.00 | 0.00 | 0.00 | -0.02 | -0.03 |
| Gross Margin | 47.8% | 47.8% | 46.0% | 22.2% | -10.0% |
| Operating Margin | 11.3% | 11.3% | 6.9% | -27.1% | -51.3% |
| Net Margin | 8.1% | 8.1% | 6.6% | -36.5% | -62.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.33 | 0.23 | 0.35 |
| Current Ratio | 1.00 | 1.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $166000.00 | $166000.00 | $-1.5M | $-7.3M | $-6.7M |
| Returns | |||||
| ROE | 5.0% | 5.0% | 3.7% | -21.7% | -31.7% |
| Valuation | |||||
| P/E | 19.42 | 19.42 | 93.67 | — | — |
| EV/EBITDA | 19.19 | 19.19 | 18.03 | — | — |
| P/B | 2.57 | 2.57 | 4.17 | 4.46 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | 25.9% | 25.9% | -5.1% | 101.4% | — |
| EPS Growth | 33.3% | 33.3% | 115.0% | 38.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
62.7%
EPS terminal req.
$0.02
Spread vs growth
-29.4%
5Y implied EPS CAGR
39.1%
EPS terminal req.
$0.02
Spread vs growth
-5.8%
10Y implied EPS CAGR
23.7%
EPS terminal req.
$0.03
Spread vs growth
9.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.6%
Start / end P/E
58.0x → 48.5x
EPS bridge
0.00 → 0.00
Residual
-5.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.